A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Conditions: Triple Negative Breast Cancer; High Grade Serous Ovarian Cancer; Endometrial Cancer Interventions: Drug: AO-252 Sponsors: A2A Pharmaceuticals Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials